GSK Valuation
Is G1SK34 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of G1SK34 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: G1SK34 (R$39.48) is trading below our estimate of fair value (R$105.81)
Significantly Below Fair Value: G1SK34 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for G1SK34?
Key metric: As G1SK34 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is G1SK34's PE Ratio? | |
|---|---|
| PE Ratio | 21.8x |
| Earnings | UK£2.51b |
| Market Cap | UK£54.76b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.1x |
| Enterprise Value/EBITDA | 7.2x |
| PEG Ratio | 1x |
Price to Earnings Ratio vs Peers
How does G1SK34's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 20.5x | ||
HYPE3 Hypera | 8.1x | 13.9% | R$12.8b |
OFSA3 Ouro Fino Saúde Animal Participações | 13.4x | n/a | R$1.2b |
4519 Chugai Pharmaceutical | 27.6x | 6.2% | JP¥10.3t |
ZTS Zoetis | 32.9x | 9.9% | US$79.8b |
G1SK34 GSK | 21.8x | 21.9% | R$54.8b |
Price-To-Earnings vs Peers: G1SK34 is expensive based on its Price-To-Earnings Ratio (21.8x) compared to the peer average (20.3x).
Price to Earnings Ratio vs Industry
How does G1SK34's PE Ratio compare vs other companies in the Global Pharmaceuticals Industry?
| 24 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 24 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: G1SK34 is good value based on its Price-To-Earnings Ratio (21.8x) compared to the Global Pharmaceuticals industry average (22.5x).
Price to Earnings Ratio vs Fair Ratio
What is G1SK34's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 21.8x |
| Fair PE Ratio | 22.8x |
Price-To-Earnings vs Fair Ratio: G1SK34 is good value based on its Price-To-Earnings Ratio (21.8x) compared to the estimated Fair Price-To-Earnings Ratio (22.8x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Novartis
CHF 187.3b
Engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally.
N1VS34
CHF 60.90
7D
2.3%
1Y
26.5%
BeiGene
US$20.2b
An oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.
B1GN34
US$45.36
7D
0%
1Y
n/a
Blau Farmacêutica
R$2.6b
A pharmaceutical company provides high-complpexity drugs in Brazil, Argentina, Chile, Colombia, Uruguay, Ecuador, Peru, and the United States.
BLAU3
R$14.70
7D
-0.9%
1Y
-9.3%